TXMD (TherapeuticsMD) Short-Term Debt & Capital Lease Obligation : $1.01 Mil (As of Mar. 2025)

View and export this data going back to 2002. Start your Free Trial

What is TherapeuticsMD Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. TherapeuticsMD's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $1.01 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. TherapeuticsMD's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $5.96 Mil.

TherapeuticsMD Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for TherapeuticsMD's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Short-Term Debt & Capital Lease Obligation Chart

TherapeuticsMD Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

2.25

189.63

1.39

1.47

1.63

TherapeuticsMD Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															1.48	1.59	1.62	1.63	1.01

TherapeuticsMD Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

TherapeuticsMD Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

TherapeuticsMD Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

29TA:Germany

Address

951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431

Website

https://www.therapeuticsmd.com

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

Executives

Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Marlan D Walker	officer: General Counsel	951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Collins Cooper C.	director	33219 FOREST WEST DRIVE, MAGNOLIA TX 77354
Joseph Ziegler	officer: Principal Financial Officer	1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan	officer: CAO and VP of Finance	6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp	10 percent owner	155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick	director	951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman	officer: Chief Business Officer	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts	director	C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Jules A. Musing	director	9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Karen Ling	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Angus C. Russell	director	C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Paul Bisaro	director
David Efraim Rosen	10 percent owner	155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017